24 September 2018 - Today, Gilead announced a plan to introduce a generic version of our leading cures for hepatitis C (HCV) in the United States more than a decade before the expiration of the patents.

We made this unusual decision because we believe that it is the fastest way to lower list prices for our HCV cures without significant disruption to the healthcare system and our business, as a bridge to longer term solutions aimed at reducing patients’ out-of-pocket medication costs, improving access for Medicaid patients and providing greater pricing transparency.

When I began working in the biopharmaceutical industry more than 30 years ago, I understood the mandate, as a scientist, to use every tool we had to make a meaningful difference in improving people’s lives ̶ to pursue breakthroughs, even cures, and eliminate serious diseases. HCV is one of those diseases.

Read Gilead press release